ARS Pharmaceuticals IncSPRY
Price$4.31

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $116.9M+31.2% YoYTTM through 30 Jun 2026
Net Income -$215.4M-2,793.6% YoYTTM through 30 Jun 2026
Free Cash Flow -$196.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin72.2%
EBITDA Margin-183.6%
Operating Margin-264.8%
Net Margin-184.2%

Returns

-322.9%ROE
-68.9%ROA

Balance Sheet Health

Debt / Equity1.57x
Current Ratio4.94x
Net Debt-$104.4Mnet cash position
Cash & Equivalents$8.2M

Quality Metrics

Altman Z-Score-2.88
Piotroski F-Score3 / 9
FCF Margin-168.1%
Rule of 40-155.0
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'21'22'23'24'25
FY2025: $84.3M
Diluted EPS-$2.18TTM
'21'22'23'24'25
FY2025: $-1.74

Dividend

No dividend

Capital Allocation

R&D Spend$15.2M
Capex Intensity0.2%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.